Immuneel Therapeutics & Manas AI Join Hands to Advance AI-Based Drug Discovery

Immuneel will combine its integrated research and development, translational science, and GMP-grade biomanufacturing capabilities with Manas AI’s computational discovery platform.

Immanuneel Therapeutics and Manas AI have announced a strategic partnership aimed at leveraging AI in the development of the next drug discovery for complex therapeutics.

The new collaboration seeks to evaluate how Immuneel might leverage Manas AI’s neuro-symbolic models and discovery engine to streamline the development of advanced biologics, multi-specific antibodies, ADCs, and in vivo gene-based therapies.

Under the agreement, Immuneel will combine its integrated research and development, translational science, and GMP-grade biomanufacturing capabilities with Manas AI’s computational discovery platform.

This is expected to shorten drug development timelines, improve predictability in therapeutic design, and accelerate the delivery of treatments for diseases with high unmet medical need, including cancer and autoimmune disorders.

Further, collaboration may include designing AI-optimized binders, payload and linker discovery for ADCs, manufacturability screening, and exploration of approaches for allogeneic and in-vivo delivery systems.

Additionally, the companies plan to evaluate establishing a closed-loop process from AI-driven in-silico design through preclinical testing and scalable manufacturing, to enable faster iteration and improved development pathways.

Highlighting the potential impact of the partnership, Amit Mookim, Chief Executive Officer, Immuneel Therapeutics, said, “By combining Immuneel’s R&D, clinical-grade manufacturing, and translational pathways with Manas AI’s discovery engine, we aim to compress development timelines and advance a new paradigm for safer and more effective therapeutic assets that can reach patients sooner.”

Reiterating similar thoughts, Dr Siddhartha Mukherjee, Co-founder of Immuneel Therapeutics and Founder and CEO of Manas AI, said AI-guided design could materially improve the precision and safety of advanced therapies.

“This partnership enables preliminary, side-by-side evaluation—from computational selection and biophysical validation to preclinical screening with the goal of responsibly advancing multi-specific designs, optimised linker-payload combinations, and in vivo delivery approaches at speed, he further added.

Stay tuned for more such updates on Digital Health News